This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary CD19 Therapeutic Antibody Development
As therapeutic antibodies continue to emerge as promising treatments, they offer new solutions for various diseases in companion animals. Selecting the right and effective target is the cornerstone of developing veterinary therapeutic antibodies. Leveraging its comprehensive platform for veterinary therapeutic antibody development, BioVenic offers antibody development services targeting CD19, assisting you in developing therapeutic antibodies against the CD19-encoded protein, thereby advancing the treatment of cancer and autoimmune diseases in canines and felines.
Background of CD19
| Full Name | Cluster of Differentiation 19 |
|---|---|
| Aliases | B4, CVID3. |
| Target Profile | The protein encoded by CD19 belongs to the immunoglobulin (Ig) superfamily and is primarily expressed on the surface of B cells. It is commonly used as a marker for B cells. CD19 plays a crucial regulatory role in B cell development and function. It acts as a co-receptor, participating in B cell activation and cooperating with other receptors to regulate B cell activation, proliferation, and signal transduction. Additionally, it is involved in B cell signaling and mediates T cell killing of target cells. |
MoA of CD19
In collaboration with CD21, CD81, and CD225, CD19 contributes to lowering the activation threshold of BCR-mediated signaling. This complex formation allows for the recruitment and binding of various downstream protein kinases, resulting in the phosphorylation and activation of PI3K. Subsequently, Akt is activated, initiating the mTOR pathway and facilitating protein synthesis and cell growth. Additionally, CD19 interacts with the Src family kinases, further enhancing BCR signal transduction.
Fig.1 Schematic diagram of CD19 signaling.1,2
Application in Veterinary Therapeutics
CD19 is frequently and highly expressed in B-cell malignancies, and its expression in normal tissues is tightly restricted to the B-cell lineage. Therefore, it can serve as a potential therapeutic target for canines with B-cell malignancies and autoimmune diseases such as systemic lupus erythematosus (SLE). CD19 therapeutic antibodies are designed to selectively bind to the CD19 antigen, ensuring that the antibodies primarily target the antigen of interest while minimizing the impact on normal cells. Upon binding, these antibodies trigger immune responses through antibody-dependent cell cytotoxicity (ADCC), direct cytotoxicity, and antibody-dependent cell phagocytosis, exerting their antigen-specific effects.
Veterinary CD19 Therapeutic Antibody Development Services
As a prominent research target, CD19 is at the forefront of therapeutic antibody development, and BioVenic offers specialized services for veterinary CD19 therapeutic antibody development. We have established several cutting-edge platforms, including hybridoma technology, single B cell technology, and phage display technology, to assist in developing high-quality CD19 antibodies. Additionally, we provide services for the characterization and engineering of veterinary therapeutic antibodies to optimize their performance. Due to the relatively low sequence homology in the extracellular domains of CD19 across different species, antibodies generated against CD19 are often species-specific. Recognizing this challenge, Biovenic offers species-specific antibody development services to advance the production of high-quality CD19 therapeutic antibodies for various species such as canines, felines, and more.
Please click the link below for more information on veterinary CD19 therapeutic antibody development services.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
In response to the species-specificity of CD19, we offer antibody caninization/felinization and fully canine/feline antibody development services.
Our engineering modifications help maintain high affinity in veterinary CD19 therapeutic antibodies.
Stringent quality control processes and multiple analytical tests ensure the high purity and safety of antibody samples.
As CD19 is a crucial surface marker on B cells associated with various animal diseases, such as B cell malignancies, autoimmune diseases, and inflammatory conditions, it holds great potential as a therapeutic target for companion animals like canines and felines. BioVenic provides a complete suite of veterinary CD19 therapeutic antibody development services, including species-specific antibody development to address its species specificity. If you have a project in mind for the development of veterinary CD19 therapeutic antibodies, please don't hesitate to contact us now.
References
- Limon, Jose J., and David A. Fruman. "Akt and mTOR in B cell activation and differentiation." Frontiers in immunology 3 (2012): 228.
- Image retrieved from Figure 1 "This diagram of BCR/CD19-initiated signaling shows two key outcomes of PI3K activation.", Limon, Jose J., and David A. Fruman., 2012, used under [CC BY 4.0], the image title was changed to "Schematic diagram of CD19 signaling."